Millennium Management LLC Lowers Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Millennium Management LLC reduced its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 44.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 790,105 shares of the biotechnology company's stock after selling 634,095 shares during the quarter. Millennium Management LLC owned 0.38% of BioCryst Pharmaceuticals worth $5,942,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Lazard Asset Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 68.1% during the fourth quarter. Lazard Asset Management LLC now owns 161,516 shares of the biotechnology company's stock worth $1,214,000 after buying an additional 65,420 shares during the period. Vanguard Group Inc. boosted its holdings in BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after acquiring an additional 1,583,826 shares during the period. Teacher Retirement System of Texas grew its position in BioCryst Pharmaceuticals by 25.1% in the 4th quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company's stock valued at $438,000 after acquiring an additional 11,711 shares in the last quarter. Raymond James Financial Inc. acquired a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $80,000. Finally, Charles Schwab Investment Management Inc. increased its stake in BioCryst Pharmaceuticals by 4.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock worth $14,890,000 after purchasing an additional 91,998 shares during the period. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded down $0.15 during trading hours on Friday, hitting $10.73. The stock had a trading volume of 3,215,552 shares, compared to its average volume of 3,031,810. The firm has a market capitalization of $2.25 billion, a PE ratio of -17.59 and a beta of 1.08. The stock's 50 day moving average is $8.61 and its 200 day moving average is $8.13. BioCryst Pharmaceuticals, Inc. has a twelve month low of $5.92 and a twelve month high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. BioCryst Pharmaceuticals's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.28 EPS. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. JMP Securities restated a "market outperform" rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Wedbush began coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective on the stock. Needham & Company LLC lifted their target price on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. upped their price target on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of "Buy" and an average target price of $16.56.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.